Last reviewed 2026-04-23 · How we verify

GBCAs

Gadolinium-based contrast agents work by providing a contrast between the magnetic properties of tissues and the surrounding environment, allowing for better visualization of internal structures during MRI scans.

Gadolinium-based contrast agents work by providing a contrast between the magnetic properties of tissues and the surrounding environment, allowing for better visualization of internal structures during MRI scans. Used for Contrast enhancement in MRI scans.

At a glance

Mechanism of action

Gadolinium-based contrast agents contain a gadolinium ion that is chelated to a ligand, which is then administered intravenously. The gadolinium ion accumulates in areas with high blood flow and is excreted through the kidneys, providing a contrast between the magnetic properties of tissues and the surrounding environment, allowing for better visualization of internal structures during MRI scans.

Approved indications

• Contrast enhancement in MRI scans

Common side effects

• Nephrogenic systemic fibrosis

Key clinical trials

• A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients (PHASE2, PHASE3)
• Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
• Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System (NA)
• Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
• A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (PHASE3)
• A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems (PHASE3)
• An Observational Study to Collect Information on the Safety of Gadolinium-Based Contrast Agents in Patients in India
• Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.